Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor combined with bifidobacterium in treatment of oral mucositis after chemotherapy
Lan? Qinghua 1, Zeng Qingfang 1, Xiao Wei 2, Zhan Tao 1,Zhong Jianming 1, Qiu Liujin 1

DOI: 10.12201/bmr.202505.00045

•  

  Abstract: Objective: To investigate the clinical efficacy of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) combined with bifidobacterium in the treatment of oral mucositis after chemotherapy. Methods: 60 patients with oral mucositis after chemotherapy treated in Ganzhou Cancer Hospital from 2022.08 to 2024.12 were selected and divided into group observation and group control, n=30. The group control was gargled with rhGM-CSF, and the observation group was orally supplemented with bifidobacterium triplex viable tablets. After 2 weeks of treatment, the clinical efficacy, symptom score, inflammatory factor level, oral microecological index and treatment safety were evaluated. Results: The group observation total effective rate was higher than group control (P<0.05). Group observation symptom scores including edema, congestion, ulcer and visual analogue scale (VAS) were lower than group control (P<0.05). The group observation inflammatory factors toll-like receptor 4(TLR4), Galectin-3 (Galectin-3) and interleukin-8 (IL-8) were lower than group control (P<0.05). the oral microflora including Lactobacillus and bifidobacterium in observation group were higher than those in control group, while porphyromonas gingivalis and Forsetanella were lower than group control (P<0.05). There difference was no incidence of adverse reactions between the two groups (P>0.05). Conclusion: Recombinant human granulocyte-macrophage colony-stimulating factor combined with bifidobacterium has significant clinical efficacy in the treatment of oral mucositis after chemotherapy, which can reduce the symptoms of patients, inhibit the expression of inflammatory factors, improve the oral microecological, and the treatment is safe.

  Key words: chemotherapy; Oral mucositis; Bifidobacterium; Recombinant human granulocyte-macrophage colony-stimulating factor; Clinical effect; Oral microecology

  Submit time: 29 May 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• 任前军, Lisu, Chenyuqing, luweiqing, mengxiaozu, Zhaoxiaofang, Liuxudong. Research Progress of Granulocyte Colony Stimulating Factor in the Treatment of Liver Failure. 2025. doi: 10.12201/bmr.202505.00003

  刘永珍, Wang ling, Liu Fu Ron. Medication patterns of traditional Chinese medicine in the treatment of radiotherapy-induced oral mucositis:A study based on data mining. 2025. doi: 10.12201/bmr.202504.00049

  李娜, Luo bingqing. Clinical observation of microwave ablation combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer.. 2025. doi: 10.12201/bmr.202504.00054

  Long Yuanyuan, Pu Jiale, Zhang Zengyu, Shen Zihao, Zhang Jidong. ZHANG Jierong1, LONG Yuanyuan1, PU Jiale1, ZHANG Zengyu1,2, SHEN Zihao1, ZHANG Jidong1*(Hunan University of Chinese Medicine,Changsha,410208,China;. 2024. doi: 10.12201/bmr.202409.00005

  Qiu Jifang, Zhou Peihua, Zeng Qianqian, Hu Hanyin. Application and effectiveness evaluation of transcranial direct current stimulation in the rehabilitation of swallowing function in stroke patientsLi Jingjing1, Qiu Jifang2, Zhou Peihua3, Zeng Qianqian1, Hu Hanyin1. 2024. doi: 10.12201/bmr.202411.00060

  胡杨, sun guang chen. Investigating the Role of Escin in RAW 264.7 Macrophage Inflammatory Models. 2025. doi: 10.12201/bmr.202504.00003

  wang zhong. Plasma C1q/ tumor necrosis factor-associated protein 6 and systemic inflammatory response index levels in patients with heart failure and their clinical significance. 2025. doi: 10.12201/bmr.202501.00060

  DAI Xin-zhen, LIAO Yan-ting, LUO Xiao-wan, FU Li-hua. LUO Yan-yan1, DAI Xin-zhen2, LIAO Yan-ting1, LUO Xiao-wan2, FU Li-hua1. 2024. doi: 10.12201/bmr.202410.00056

  cheng aijun. 1. 2022. doi: 10.12201/bmr.202211.00007

  马亚鑫, ZHU Xiaowei, Li Shuqiong, Li Yunxiang, Sun Yonghong. MA Yaxin1, LI Shuqiong1, LI Yunxiang1, SUN Yonghong2▲. 2025. doi: 10.12201/bmr.202504.00073

• ID	Submit time	Number	Download
  1	2025-04-20	bmr.202505.00045V1	Download

• Public  Anonymous  To author only Submit Comments